UBS analyst Trung Huynh raised the firm’s price target on Pfizer (PFE) to $25 from $24 and keeps a Neutral rating on the shares. While Pfizer had a “mixed” revenue performance, cost savings were significant, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Notable open interest changes for April 30th
- Pfizer Positioned for Growth: Buy Rating Affirmed Due to Operational Efficiency, Strategic Capital Allocation, and Undervaluation
- Pfizer’s Mixed Q1 Results and Uncertain Long-Term Prospects Justify Hold Rating
- Pfizer Reports Strong Q1 2025 Results and Reaffirms Guidance
- Pfizer’s Hold Rating: Balancing Cost Efficiency with Revenue Growth and Strategic Expansion